What's Happening?
Arrowhead Pharmaceuticals has announced that its drug, plozasiran, has been granted entry into the United States Food and Drug Administration (FDA) Split Real Time Application Review (STAR) pilot program. This entry is in anticipation of Arrowhead's upcoming
supplemental new drug application (sNDA) for severe hypertriglyceridemia (sHTG). The FDA STAR pilot program is designed to expedite the review process for certain supplemental indications for already-approved drugs, aiming to shorten the time from a complete sNDA submission to the action date. To qualify for the STAR program, the FDA must determine that clinical evidence indicates the drug may offer substantial improvement over existing therapies for a clinically relevant endpoint. Plozasiran, marketed as REDEMPLO®, is already approved in the U.S., EU, China, Australia, and Canada as an adjunct to diet for reducing triglycerides in adults with familial chylomicronemia syndrome (FCS), the most severe form of sHTG. Arrowhead Pharmaceuticals plans to submit the sNDA for plozasiran in sHTG to the FDA by the end of 2026.
Why It's Important?
The inclusion of plozasiran in the FDA STAR pilot program is significant because it aims to accelerate patient access to a therapy addressing an unmet medical need. Severe hypertriglyceridemia (sHTG) is a condition characterized by high triglyceride levels, which substantially increases the risk of acute pancreatitis, a potentially fatal condition requiring frequent hospitalizations. Current treatment options for sustainably reducing triglycerides below recommended thresholds are limited. By shortening the review timeline, the STAR program could bring plozasiran to patients with sHTG more quickly, potentially reducing the incidence of acute pancreatitis and improving patient outcomes. This expedited review also provides a strategic advantage for Arrowhead Pharmaceuticals, as it secures a 6-month Priority Review without needing to use a Priority Review Voucher (PRV), which can be redeployed for future applications or monetized. This could set a precedent for other pharmaceutical companies developing therapies for conditions with significant unmet medical needs.
What's Next?
Arrowhead Pharmaceuticals is on track to submit its supplemental new drug application (sNDA) for plozasiran in severe hypertriglyceridemia (sHTG) to the FDA by the end of 2026. Following this submission, the drug will undergo an expedited review process under the FDA STAR pilot program, which targets an action date at least one month before the standard 6-month Priority Review goal. This accelerated timeline means a decision on plozasiran for sHTG could come as early as mid-2027. If approved, Arrowhead Pharmaceuticals plans to seek regulatory approval with additional global regulatory authorities. The company will also need to work with healthcare providers and payers to ensure access and reimbursement for the expanded indication, building on its existing approvals for familial chylomicronemia syndrome (FCS). The success of plozasiran in the STAR program could also encourage other pharmaceutical companies to pursue similar expedited pathways for their own therapies addressing critical unmet medical needs.
Beyond the Headlines
The FDA STAR pilot program's acceptance of plozasiran highlights a broader trend in pharmaceutical regulation towards accelerating the availability of therapies for serious conditions with limited treatment options. This initiative reflects a recognition by regulatory bodies of the urgent need to bridge the gap between drug development and patient access, particularly for diseases that pose significant health risks and burden healthcare systems. The program's focus on 'substantial improvement' over existing therapies underscores a commitment to innovation that truly benefits patients. Furthermore, the strategic decision by Arrowhead Pharmaceuticals to leverage this program, rather than using a Priority Review Voucher, demonstrates a sophisticated understanding of regulatory pathways and resource optimization. This could influence future drug development strategies, encouraging companies to prioritize therapies that meet the stringent criteria for expedited review, thereby potentially shifting investment towards areas of high unmet medical need and fostering a more responsive regulatory environment.
